Accel Diagnostics is a medical diagnostics company developing proprietary point-of-care diagnostic assays for the diagnosis, monitoring, and management of various conditions. The company has proposed an innovative blood diagnostic test to aid the triage of patients presenting with head injuries, supported by SBIR funding.

ALung Technologies, Inc. is a Pittsburgh-based medical device company that developed low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with respiratory failure. The company originated from the University of Pittsburgh and was acquired by LivaNova PLC in July 2022.

ARIEL Precision Medicine is a Pittsburgh, PA-based company pioneering the integration of genomic and clinical data to transform complex data into actionable healthcare insights. It has developed decision-support tools that integrate complex genetics into clinical decision making, focused on chronic diseases with high unmet need.

Astria Biosciences is a Pittsburgh-based startup developing blood-based diagnostics and small molecule inhibitors to combat cerebrovascular and neurovascular diseases. The company targets conditions such as aneurysm and craniofacial synostosis and has received NSF support.

Biointerphase is a mission-driven bioengineering studio dedicated to restoring and reinforcing biological needs through sustainable biointerfaces. The company combines bioengineering with sustainable design to create impactful products for healthcare, with roots at the University of Pittsburgh.

Cassian Solutions is a healthcare technology company focused on patient and healthcare provider interactions within the specialty pharmacy and health plan sectors. Its ONE Journey™ platform delivers dynamic patient support programs with real-time insights for specialty care.

Cell X Technologies is a life sciences company pioneering advanced cell processing automation through its Celligent platform, designed to advance cellular and regenerative therapies. The company collaborates with reagent and biotech partners to standardize iPSC-based therapeutics and improve manufacturing for cell therapy innovators.

Cellumen, Inc. was a Pittsburgh, PA-based cellular systems biology company providing drug efficacy and toxicity prediction solutions. Founded with backing from Innovation Works, the company was acquired by Apredica (later Cyprotex) and partnered with firms such as Mitsubishi Tanabe Pharma Corporation.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Purchase, New York, focused on the discovery and development of small-molecule therapeutics targeting age-related neurodegenerative diseases of the central nervous system and retina. The company trades on NASDAQ under the ticker CGTX.

CranioSense is a clinical-stage medical device company developing IPASS, a non-invasive technology that measures intracranial pressure in seconds using a forehead patch and handheld reader — without drilling into the skull or inserting a sensor. The company is on a mission to enable on-demand neurological insight and treatment.

CytoAgents is a clinical-stage biotechnology company developing innovative pharmaceutical products for life-threatening conditions. Its lead asset, CTO1681, is an oral small molecule immune modulator designed to prevent and treat Cytokine Release Syndrome and other inflammatory conditions through selective prostacyclin/prostaglandin receptor signaling.

DermaBio is a precision medicine company developing a skin biomarker platform to improve diagnosis, monitoring, and treatment selection for chronic and autoimmune inflammatory diseases. Founded in 2022, the company applies dermatological biomarkers to enable more targeted therapeutic decisions.

Diamyd, Inc. (formerly Nurel Therapeutics) is a gene therapy company acquired by Diamyd Medical AB in December 2005. Originally focused on a proprietary targeted drug delivery technique called Nerve-Targeted Gene Delivery, the company was subsequently integrated into Diamyd Medical's diabetes pipeline.

Duo Oncology is a biotech company founded by oncologists that develops ultrasmall, tumor-penetrating nanomedicines delivering drug combinations to deep, difficult-to-target tumors. The company aims to redefine cancer care by reinvigorating the treatment landscape with tumor-responsive nanomedicine approaches.

Endolumik is a medical device company founded in Morgantown, West Virginia, developing fluorescence-guided surgical tools for laparoscopic and bariatric procedures. Its patented devices enhance visualization and safety during gastrointestinal surgery. San Juan Regional Medical Center introduced its novel fluorescent device to New Mexico in 2023.

FlowCellutions is an early-stage clean energy tech startup that provides real-time monitoring and diagnostic tools for grid-scale battery systems. Its first-of-its-kind sensor technology targets a $45B market in energy storage. The company is a member of Greentown Labs.

Formation Bio is an AI-native pharmaceutical company that acquires clinical-stage drug candidates from pharma companies, universities, and biotech firms and develops them faster and more efficiently using proprietary technology. The company combines the best of tech and pharma to scale drug development and transform the industry.

FutureDerm, Inc. was a skincare company focused on science-backed beauty products, subsequently acquired by Columbia Skincare, a medical-grade microbiome-friendly skincare brand based in the US.

Gus Gear makes wearable securement clothing to protect implanted medical devices such as central catheters and feeding tubes, improving safety and quality of life for patients facing medical challenges. The company was founded by Sarah Palya, whose personal experience with her son Gus inspired the product line.

HexemBio is a biotechnology company developing regenerative therapies based on its Synthetic Human Yolk Sac technology, designed to rejuvenate aging blood stem cells. The company launched in 2026 with a $10.4M seed round led by Draper Associates. It aims to create the first scalable and reproducible rejuvenation therapy targeting early developmental cell states.